Axxam and Mercachem Sign a Strategic Alliance for Integrated Drug Discovery Services
Axxam, a leading drug discovery company with expertise in early phase discovery biology, and Mercachem, a leading discovery chemistry company with expertise in both medicinal and process chemistry, announce a strategic alliance to provide integrated discovery services spanning all phases from gene to fully optimized leads and beyond. This partnership will allow the companies to offer best-in-class fully integrated drug discovery services, supported by a culture of scientific excellence and innovation. The combination of the two companies' platforms, each with a long-standing reputation and track record of scientific excellence and delivery for their partners, provides to partners a seamless combination of robust assay development, high throughput screening, hit validation and subsequent medicinal chemistry optimization for a wide range of innovative and challenging biological targets. For more information: www.axxam.com and www.mercachem.com.
Molmed: the European Commission grants a Conditional Marketing Authorisation to Zalmoxis®, the first immunogene therapy for the treatment of adult patients with high-risk haematological malignancies
MolMed S.p.A. announced today that the European Commission has granted a Conditional Marketing Authorisation (CMA) for Zalmoxis, the first immunogene therapy, as patient-specific adjunctive treatment in haplo-identical haematopoietic stem-cell transplantation (HSCT) for adult patients with high-risk haematological malignancies. Zalmoxis innovative therapy is based on genetically engineering donor immune system T cells to carry an inducible “suicide gene”. Administered to patients following HSCT from partially compatible donors (haplo-identical HSCT), these cells foster an anti-leukemia effect by eliminating post-transplant immunosuppression prophylaxis and inducing a rapid immune reconstitution. The suicide gene allows to readily control Graft versus Host Disease (GvHD), the most significant and serious adverse event in haplo-identical transplantation, caused by the genetic disparity between patient and donor. Zalmoxis significantly increases long-term survival, regardless of disease status at transplant, thus making HSCT from partially compatible donors safer and more effective. For more information: http://www.molmed.com/sites/default/files/uploads/press-releases/2907/2907_1471829992.pdf
Genenta Science, Amgen, Ospedale San Raffaele deal
Genenta, San Raffaele and Amgen partnered to evaluate myeloid-targeted hematopoietic stem cell (HSC) therapies to treat cancer. The partners will use Genenta’s HSC platform, which it licensed from San Raffaele.
Genenta’s prospective cancer therapy involves taking hematopoietic stem cells from a patient and
transducing them with a lentiviral vector carrying the gene for interferon alpha. The modified stem cells are
then reinjected into the patient where they migrate to specific monocytes and macrophages. The monocytes
and macrophages then release interferon alpha into the tumour microenvironment where they can kill the
tumour. “The point about our technology is that we have the capability to express interferon alpha inside the tumour microenvironment. We change the balance inside the tumour microenvironment by supporting the immune system to fight cancer thanks to the local expression of interferon alpha,” Mr Paracchi said. For more information: http://www.hsr.it/press-releases/genenta-e-ospedale-san-raffaele-annunciano-una-collaborazione-strategica-con-amgen-per-testare-la-terapia-genica-con-cellule-staminali-ematopoietiche-in-ambito-oncologico/
Bio-on: nanotechnologies and bioplastic to diagnose and combat tumours
For the very first time, bioplastic can be used to diagnose and treat tumours thanks to the first patent registered by Bio-on in the nanomedical field, particularly in nanodiagnostics (nano-imaging). Bio-on researchers use nanotechnologies to create minerv BIOMEDS: these are revolutionary and innovative nanocapsules in PHAs bioplastic (polyhydroxyalkanoates) capable of simultaneously containing two contrast media: magnetic nanoparticles and gold nanocylinders. These two elements flag up diseased areas of the body, e.g. a tumour mass, using traditional Nuclear Magnetic Resonance and the more innovative Photoacoustic imaging. For more information: http://www.bio-on.it/immagini/comunicati-finanziari/CS_64_BIO-ON_teranostica_19_09_2016_EN.pdf